{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:36:28Z","timestamp":1794656188488,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["JC-358161"],"award-info":[{"award-number":["JC-358161"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","award":["PF-Launch-1275246"],"award-info":[{"award-number":["PF-Launch-1275246"]}],"id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000887","name":"Huntington's Disease Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["10039"],"award-info":[{"award-number":["10039"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","award":["RR162060"],"award-info":[{"award-number":["RR162060"]}],"id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative illness characterized by motor and non-motor features. Hallmarks of the disease include an extensive loss of dopaminergic neurons in the <jats:italic>substantia nigra pars compacta<\/jats:italic>, evidence of neuroinflammation, and the accumulation of misfolded proteins leading to the formation of Lewy bodies. While PD etiology is complex and identifying a single disease trigger has been a challenge, accumulating evidence indicates that non-neuronal and peripheral factors may likely contribute to disease onset and progression. The brain is shielded from peripheral factors by the blood-brain barrier (BBB), which tightly controls the entry of systemic molecules and cells from the blood to the brain. The BBB integrates molecular signals originating from the luminal (blood) and abluminal (brain) sides of the endothelial wall, regulating these exchanges. Of particular interest are erythrocytes, which are not only the most abundant cell type in the blood, but they also secrete extracellular vesicles (EVs) that display disease-specific signatures over the course of PD. Erythrocyte-derived EVs (EEVs) could provide a route by which pathological molecular signals travel from the periphery to the central nervous system. The primary objective of this study was to evaluate, in a human-based platform, mechanisms of EEV transport from the blood to the brain under physiological conditions. The secondary objective was to determine the ability of EEVs, generated by erythrocytes of healthy donors or patients, to induce PD-like features. We leveraged two in vitro models of the BBB, the transwell chambers and a microfluidic BBB chip generated using human induced pluripotent stem cells. Our findings suggest that EEVs transcytose from the vascular to the brain compartment of the human BBB model via a caveolin-dependant mechanism. Furthermore, EEVs derived from individuals with PD altered BBB integrity compared to healthy EEV controls, and clinical severity aggravated the loss of barrier integrity and increased EEV extravasation into the brain compartment. PD-derived EEVs reduced ZO-1 and Claudin 5 tight junction levels in BMEC-like cells and induced the selective atrophy of dopaminergic neurons. In contrast, non-dopaminergic neurons were not affected by treatment with PD EEVs. In summary, our data suggest that EEV interactions at the human BBB can be studied using a highly translational human-based brain chip model, and EEV toxicity at the neurovascular unit is exacerbated by disease severity.<\/jats:p>","DOI":"10.1186\/s12987-025-00646-9","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T12:55:27Z","timestamp":1744635327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Erythrocyte-derived extracellular vesicles transcytose across the blood-brain barrier to induce Parkinson\u2019s disease-like neurodegeneration"],"prefix":"10.1186","volume":"22","author":[{"given":"H\u00e9l\u00e8na L.","family":"Denis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"de Rus Jacquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Alpaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Panisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Boilard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"646_CR1","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature"},{"key":"646_CR2","doi-asserted-by":"publisher","first-page":"106298","DOI":"10.1016\/j.nbd.2023.106298","volume":"187","author":"K Lau","year":"2023","unstructured":"Lau K, Porschen LT, Richter F, Gericke B. Microvascular blood-brain barrier alterations in isolated brain capillaries of mice over-expressing alpha-synuclein (Thy1-aSyn line 61). Neurobiol Dis. 2023;187:106298.","journal-title":"Neurobiol Dis"},{"key":"646_CR3","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1038\/s41467-023-39038-8","volume":"14","author":"A de Rus Jacquet","year":"2023","unstructured":"de Rus Jacquet A, Alpaugh M, Denis HL, Tancredi JL, Boutin M, Decaestecker J, Beauparlant C, Herrmann L, Saint-Pierre M, Parent M, Droit A, Breton S, Cicchetti F. The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson\u2019s disease. Nat Commun. 2023;14:3651.","journal-title":"Nat Commun"},{"key":"646_CR4","doi-asserted-by":"publisher","first-page":"593026","DOI":"10.3389\/fphys.2020.593026","volume":"11","author":"S Al-Bachari","year":"2020","unstructured":"Al-Bachari S, Naish JH, Parker GJM, Emsley HCA, Parkes LM. Blood-Brain barrier leakage is increased in Parkinson\u2019s disease. Front Physiol. 2020;11:593026.","journal-title":"Front Physiol"},{"key":"646_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.20369","volume":"57","author":"R Kortekaas","year":"2005","unstructured":"Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57:176\u20139.","journal-title":"Ann Neurol"},{"key":"646_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/jcbfm.2015.32","volume":"35","author":"MT Gray","year":"2015","unstructured":"Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson\u2019s disease. J Cereb Blood Flow Metabolism: Official J Int Soc Cereb Blood Flow Metabolism. 2015;35:747\u201350.","journal-title":"J Cereb Blood Flow Metabolism: Official J Int Soc Cereb Blood Flow Metabolism"},{"key":"646_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.expneurol.2016.09.003","volume":"285","author":"WL Kuan","year":"2016","unstructured":"Kuan WL, Bennett N, He X, Skepper JN, Martynyuk N, Wijeyekoon R, Moghe PV, Williams-Gray CH, Barker RA. alpha-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function. Exp Neurol. 2016;285:72\u201381.","journal-title":"Exp Neurol"},{"key":"646_CR8","doi-asserted-by":"crossref","unstructured":"Pediaditakis I, Manatakis KKR, Hinojosa DV, Manolakos CD, Rubin ES, Hamilton LL, Karalis GA. K. Modeling Alpha-Synuclein Pathology in a Human Brain-Chip to Assess Blood-Brain Barrier Disruption in Parkinson\u2019s Disease. BioRxiv [Preprint] (2020).","DOI":"10.1101\/2020.07.22.207340"},{"key":"646_CR9","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1038\/s41467-024-48961-3","volume":"15","author":"J Hallqvist","year":"2024","unstructured":"Hallqvist J, Bartl M, Dakna M, Schade S, Garagnani P, Bacalini MG, Pirazzini C, Bhatia K, Schreglmann S, Xylaki M, Weber S, Ernst M, Muntean ML, Sixel-Doring F, Franceschi C, Doykov I, Spiewak J, Vinette H, Trenkwalder C, Heywood WE, Mills K, Mollenhauer B. Plasma proteomics identify biomarkers predicting Parkinson\u2019s disease up to 7 years before symptom onset. Nat Commun. 2024;15:4759.","journal-title":"Nat Commun"},{"key":"646_CR10","doi-asserted-by":"crossref","unstructured":"Gatarek P, Sekulska-Nalewajko J, Bobrowska-Korczaka B, Pawelczyk M, Jastrzebski K, Glabinski A, Kaluzna-Czaplinska J. Plasma Metabolic Disturbances in Parkinson\u2019s Disease Patients. Biomedicines 10 (2022).","DOI":"10.3390\/biomedicines10123005"},{"key":"646_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.29163","volume":"37","author":"D Te Vruchte","year":"2022","unstructured":"Te Vruchte D, Sturchio A, Priestman DA, Tsitsi P, Hertz E, Andreasson M, Markaki I, Wallom KL, Platt F, Svenningsson P. Glycosphingolipid changes in plasma in Parkinson\u2019s disease independent of glucosylceramide levels. Mov Disorders: Official J Mov Disorder Soc. 2022;37:2129\u201334.","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"key":"646_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","volume":"99","author":"M Zubelzu","year":"2022","unstructured":"Zubelzu M, Morera-Herreras T, Irastorza G, Gomez-Esteban JC, Murueta-Goyena A. Plasma and serum alpha-synuclein as a biomarker in Parkinson\u2019s disease: A meta-analysis. Parkinsonism Relat Disord. 2022;99:107\u201315.","journal-title":"Parkinsonism Relat Disord"},{"key":"646_CR13","doi-asserted-by":"publisher","first-page":"e848","DOI":"10.1212\/WNL.0000000000013225","volume":"98","author":"SJ Chen","year":"2022","unstructured":"Chen SJ, Chen CC, Liao HY, Lin YT, Wu YW, Liou JM, Wu MS, Kuo CH, Lin CH. Association of fecal and plasma levels of Short-Chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology. 2022;98:e848\u201358.","journal-title":"Neurology"},{"key":"646_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","volume":"18","author":"AH Tan","year":"2022","unstructured":"Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Reviews Neurol. 2022;18:476\u201395.","journal-title":"Nat Reviews Neurol"},{"key":"646_CR15","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager J, Andersen KB, Knudsen K, Skjaerbaek C, Fedorova TD, Okkels N, Schaeffer E, Bonkat SK, Geday J, Otto M, Sommerauer M, Danielsen EH, Bech E, Kraft J, Munk OL, Hansen SD, Pavese N, Goder R, Brooks DJ, Berg D, Borghammer P. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain. 2020;143:3077\u201388.","journal-title":"Brain"},{"key":"646_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D\u2019Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"646_CR17","doi-asserted-by":"publisher","first-page":"e73062","DOI":"10.7554\/eLife.73062","volume":"10","author":"A de Rus Jacquet","year":"2021","unstructured":"de Rus Jacquet A, Tancredi JL, Lemire AL, DeSantis MC, Li W-P, O\u2019Shea E. The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson\u2019s disease. eLife. 2021;10:e73062.","journal-title":"eLife"},{"key":"646_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2018.11.002","volume":"124","author":"J Lamontagne-Proulx","year":"2019","unstructured":"Lamontagne-Proulx J, St-Amour I, Labib R, Pilon J, Denis HL, Cloutier N, Roux-Dalvai F, Vincent AT, Mason SL, Williams-Gray C, Duchez AC, Droit A, Lacroix S, Dupre N, Langlois M, Chouinard S, Panisset M, Barker RA, Boilard E, Cicchetti F. Portrait of blood-derived extracellular vesicles in patients with Parkinson\u2019s disease. Neurobiol Dis. 2019;124:163\u201375.","journal-title":"Neurobiol Dis"},{"key":"646_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.tins.2024.06.005","volume":"47","author":"Y Yang","year":"2024","unstructured":"Yang Y, Nie X, Wang Y, Sun J, Gao X, Zhang J. Evolving insights into erythrocytes in synucleinopathies. Trends Neurosci. 2024;47:693\u2013707.","journal-title":"Trends Neurosci"},{"key":"646_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40478-017-0470-4","volume":"5","author":"J Matsumoto","year":"2017","unstructured":"Matsumoto J, Stewart T, Sheng L, Li N, Bullock K, Song N, Shi M, Banks WA, Zhang J. Transmission of alpha-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson\u2019s disease? Acta Neuropathol Commun. 2017;5:71.","journal-title":"Acta Neuropathol Commun"},{"key":"646_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/brain\/awf080","volume":"125","author":"AJ Hughes","year":"2002","unstructured":"Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861\u201370.","journal-title":"Brain"},{"key":"646_CR22","doi-asserted-by":"publisher","first-page":"a008870","DOI":"10.1101\/cshperspect.a008870","volume":"2","author":"J Massano","year":"2012","unstructured":"Massano J, Bhatia KP. Clinical approach to Parkinson\u2019s disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med. 2012;2:a008870.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"646_CR23","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1007\/s00415-018-9022-5","volume":"265","author":"HL Denis","year":"2018","unstructured":"Denis HL, Lamontagne-Proulx J, St-Amour I, Mason SL, Weiss A, Chouinard S, Barker RA, Boilard E, Cicchetti F. Platelet-derived extracellular vesicles in Huntington\u2019s disease. J Neurol. 2018;265:2704\u201312.","journal-title":"J Neurol"},{"key":"646_CR24","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00018-011-0689-3","volume":"68","author":"B Gyorgy","year":"2011","unstructured":"Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, Laszlo V, Pallinger E, Pap E, Kittel A, Nagy G, Falus A. Buzas, E. I. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68:2667\u201388.","journal-title":"Cell Mol Life Sci"},{"key":"646_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.stem.2013.01.008","volume":"12","author":"P Reinhardt","year":"2013","unstructured":"Reinhardt P, Schmid B, Burbulla LF, Schondorf DC, Wagner L, Glatza M, Hoing S, Hargus G, Heck SA, Dhingra A, Wu G, Muller S, Brockmann K, Kluba T, Maisel M, Kruger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Muller H, Gasser T, Scholer HR, Sterneckert J. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12:354\u201367.","journal-title":"Cell Stem Cell"},{"key":"646_CR26","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1002\/cpcb.98","volume":"85","author":"R de Jacquet","year":"2019","unstructured":"de Jacquet R. Preparation and Co-Culture of iPSC-Derived dopaminergic neurons and astrocytes. Curr Protoc Cell Biol. 2019;85:e98.","journal-title":"Curr Protoc Cell Biol"},{"key":"646_CR27","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1038\/s41467-023-39038-8","volume":"14","author":"A de Rus Jacquet","year":"2023","unstructured":"de Rus Jacquet A, Alpaugh M, Denis H, Tancredi J, Boutin M, Decaestecker J, Beauparlant C, Herrmann L, Saint-Pierre M, Parent M. The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson\u2019s disease. Nat Commun. 2023;14:3651.","journal-title":"Nat Commun"},{"key":"646_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40364-022-00404-1","volume":"10","author":"D Fortunato","year":"2022","unstructured":"Fortunato D, Giannoukakos S, Gimenez-Capitan A, Hackenberg M, Molina-Vila MA, Zarovni N. Selective isolation of extracellular vesicles from minimally processed human plasma as a translational strategy for liquid biopsies. Biomark Res. 2022;10:57.","journal-title":"Biomark Res"},{"key":"646_CR29","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/mds.29497","volume":"38","author":"M Xylaki","year":"2023","unstructured":"Xylaki M, Chopra A, Weber S, Bartl M, Outeiro TF, Mollenhauer B. Extracellular vesicles for the diagnosis of Parkinson\u2019s disease: systematic review and Meta-Analysis. Mov Disorders: Official J Mov Disorder Soc. 2023;38:1585\u201397.","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"key":"646_CR30","first-page":"1797","volume":"28","author":"M Mila-Aloma","year":"2022","unstructured":"Mila-Aloma M, Ashton NJ, Shekari M, Salvado G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, Day TA, Gonzalez-Escalante A, Sanchez-Benavides G, Minguillon C, Fauria K, Molinuevo JL, Dage JL, Zetterberg H, Gispert JD, Suarez-Calvet M, Blennow K. Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28:1797\u2013801.","journal-title":"Nat Med"},{"key":"646_CR31","doi-asserted-by":"publisher","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"R Daneman","year":"2015","unstructured":"Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7:a020412.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"646_CR32","doi-asserted-by":"crossref","unstructured":"Nilles KL, Williams EI, Betterton RD, Davis TP, Ronaldson PT. Blood-Brain barrier transporters: opportunities for therapeutic development in ischemic stroke. Int J Mol Sci 23 (2022).","DOI":"10.3390\/ijms23031898"},{"key":"646_CR33","doi-asserted-by":"crossref","unstructured":"Chen MB, Yang AC, Yousef H, Lee D, Chen W, Schaum N, Lehallier B, Quake SR, Wyss-Coray T. Brain Endothelial Cells Are Exquisite Sensors of Age-Related Circulatory Cues. Cell Rep 30, 4418\u20134432 e4414 (2020).","DOI":"10.1016\/j.celrep.2020.03.012"},{"key":"646_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2453-z","volume":"583","author":"AC Yang","year":"2020","unstructured":"Yang AC, Stevens MY, Chen MB, Lee DP, Stahli D, Gate D, Contrepois K, Chen W, Iram T, Zhang L, Vest RT, Chaney A, Lehallier B, Olsson N, du Bois H, Hsieh R, Cropper HC, Berdnik D, Li L, Wang EY, Traber GM, Bertozzi CR, Luo J, Snyder MP, Elias JE, Quake SR, James ML. Wyss-Coray, T. Physiological blood-brain transport is impaired with age by a shift in transcytosis. Nature. 2020;583:425\u201330.","journal-title":"Nature"},{"key":"646_CR35","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1021\/acsnano.9b04397","volume":"13","author":"G Morad","year":"2019","unstructured":"Morad G, Carman CV, Hagedorn EJ, Perlin JR, Zon LI, Mustafaoglu N, Park TE, Ingber DE, Daisy CC, Moses MA. Tumor-Derived extracellular vesicles breach the intact Blood-Brain barrier via transcytosis. ACS Nano. 2019;13:13853\u201365.","journal-title":"ACS Nano"},{"key":"646_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12987-022-00359-3","volume":"19","author":"HM Ramos-Zaldivar","year":"2022","unstructured":"Ramos-Zaldivar HM, Polakovicova I, Salas-Huenuleo E, Corvalan AH, Kogan MJ, Yefi CP, Andia ME. Extracellular vesicles through the blood-brain barrier: a review. Fluids Barriers CNS. 2022;19:60.","journal-title":"Fluids Barriers CNS"},{"key":"646_CR37","doi-asserted-by":"crossref","unstructured":"Banks WA, Sharma P, Bullock KM, Hansen KM, Ludwig N, Whiteside TL. Transport of extracellular vesicles across the Blood-Brain barrier: brain pharmacokinetics and effects of inflammation. Int J Mol Sci 21 (2020).","DOI":"10.3390\/ijms21124407"},{"key":"646_CR38","doi-asserted-by":"publisher","first-page":"103930","DOI":"10.1016\/j.mvr.2019.103930","volume":"128","author":"X Wang","year":"2020","unstructured":"Wang X, Xu B, Xiang M, Yang X, Liu Y, Liu X, Shen Y. Advances on fluid shear stress regulating blood-brain barrier. Microvasc Res. 2020;128:103930.","journal-title":"Microvasc Res"},{"key":"646_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2202-12-40","volume":"12","author":"L Cucullo","year":"2011","unstructured":"Cucullo L, Hossain M, Puvenna V, Marchi N, Janigro D. The role of shear stress in Blood-Brain barrier endothelial physiology. BMC Neurosci. 2011;12:40.","journal-title":"BMC Neurosci"},{"key":"646_CR40","doi-asserted-by":"publisher","first-page":"1187300","DOI":"10.3389\/fnmol.2023.1187300","volume":"16","author":"D Nieves Torres","year":"2023","unstructured":"Nieves Torres D, Lee SH. Inter-neuronal signaling mediated by small extracellular vesicles: wireless communication? Front Mol Neurosci. 2023;16:1187300.","journal-title":"Front Mol Neurosci"},{"key":"646_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/brain\/awad332","volume":"147","author":"DM Hermann","year":"2024","unstructured":"Hermann DM, Peruzzotti-Jametti L, Giebel B, Pluchino S. Extracellular vesicles set the stage for brain plasticity and recovery by multimodal signalling. Brain. 2024;147:372\u201389.","journal-title":"Brain"},{"key":"646_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40035-019-0155-y","volume":"8","author":"C Tian","year":"2019","unstructured":"Tian C, Liu G, Gao L, Soltys D, Pan C, Stewart T, Shi M, Xie Z, Liu N, Feng T, Zhang J. Erythrocytic alpha-Synuclein as a potential biomarker for Parkinson\u2019s disease. Transl Neurodegener. 2019;8:15.","journal-title":"Transl Neurodegener"},{"key":"646_CR43","doi-asserted-by":"crossref","unstructured":"Chung CC, Chan L, Chen JH, Hung YC, Hong CT. Plasma Extracellular Vesicle alpha-Synuclein Level in Patients with Parkinson\u2019s Disease. Biomolecules 11 (2021).","DOI":"10.3390\/biom11050744"},{"key":"646_CR44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.nbd.2014.12.006","volume":"74","author":"IS Pienaar","year":"2015","unstructured":"Pienaar IS, Lee CH, Elson JL, McGuinness L, Gentleman SM, Kalaria RN, Dexter DT. Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson\u2019s disease. Neurobiol Dis. 2015;74:392\u2013405.","journal-title":"Neurobiol Dis"},{"key":"646_CR45","doi-asserted-by":"publisher","first-page":"1506358","DOI":"10.3389\/fnins.2024.1506358","volume":"18","author":"AR Trainor","year":"2024","unstructured":"Trainor AR, MacDonald DS, Penney J. Microglia: roles and genetic risk in Parkinson\u2019s disease. Front Neurosci. 2024;18:1506358.","journal-title":"Front Neurosci"},{"key":"646_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.stemcr.2018.12.011","volume":"12","author":"A di Domenico","year":"2019","unstructured":"di Domenico A, Carola G, Calatayud C, Pons-Espinal M, Munoz JP, Richaud-Patin Y, Fernandez-Carasa I, Gut M, Faella A, Parameswaran J, Soriano J, Ferrer I, Tolosa E, Zorzano A, Cuervo AM, Raya A, Consiglio A. Patient-Specific iPSC-Derived astrocytes contribute to Non-Cell-Autonomous neurodegeneration in Parkinson\u2019s disease. Stem Cell Rep. 2019;12:213\u201329.","journal-title":"Stem Cell Rep"},{"key":"646_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40478-020-00983-w","volume":"8","author":"L Sheng","year":"2020","unstructured":"Sheng L, Stewart T, Yang D, Thorland E, Soltys D, Aro P, Khrisat T, Xie Z, Li N, Liu Z, Tian C, Bercow M, Matsumoto J, Zabetian CP, Peskind E, Quinn JF, Shi M, Zhang J. Erythrocytic alpha-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson\u2019s disease pathogenesis. Acta Neuropathol Commun. 2020;8:102.","journal-title":"Acta Neuropathol Commun"},{"key":"646_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mds.29620","volume":"39","author":"Y Yang","year":"2024","unstructured":"Yang Y, Stewart T, Zhang C, Wang P, Xu Z, Jin J, Huang Y, Liu Z, Lan G, Liang X, Sheng L, Shi M, Cai Z, Zhang J. Erythrocytic alpha-Synuclein and the gut microbiome: kindling of the gut-Brain axis in Parkinson\u2019s disease. Mov Disorders: Official J Mov Disorder Soc. 2024;39:40\u201352.","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"key":"646_CR49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41580-020-00313-x","volume":"22","author":"AJ Covarrubias","year":"2021","unstructured":"Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22:119\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"646_CR50","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cmet.2019.09.001","volume":"30","author":"S Lautrup","year":"2019","unstructured":"Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD(+) in brain aging and neurodegenerative disorders. Cell Metab. 2019;30:630\u201355.","journal-title":"Cell Metab"},{"key":"646_CR51","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1038\/s41467-023-43514-6","volume":"14","author":"H Berven","year":"2023","unstructured":"Berven H, Kverneng S, Sheard E, Sognen M, Af Geijerstam SA, Haugarvoll K, Skeie GO, Dolle C, Tzoulis C. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson\u2019s disease. Nat Commun. 2023;14:7793.","journal-title":"Nat Commun"},{"key":"646_CR52","doi-asserted-by":"crossref","unstructured":"Brakedal B, Dolle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmuller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Gruner R, Eidelberg D, Tzoulis C. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson\u2019s disease. Cell Metab 34, 396\u2013407 e396 (2022).","DOI":"10.1016\/j.cmet.2022.02.001"},{"key":"646_CR53","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1038\/s41380-022-01511-z","volume":"27","author":"EG Knox","year":"2022","unstructured":"Knox EG, Aburto MR, Clarke G, Cryan JF, O\u2019Driscoll CM. The blood-brain barrier in aging and neurodegeneration. Mol Psychiatry. 2022;27:2659\u201373.","journal-title":"Mol Psychiatry"},{"key":"646_CR54","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1750-3639.2012.00628.x","volume":"23","author":"J Guan","year":"2013","unstructured":"Guan J, Pavlovic D, Dalkie N, Waldvogel HJ, O\u2019Carroll SJ, Green CR. Nicholson, L. F. Vascular degeneration in Parkinson\u2019s disease. Brain Pathol. 2013;23:154\u201364.","journal-title":"Brain Pathol"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-025-00646-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:03:36Z","timestamp":1751544216000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-025-00646-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1186\/s12987-025-00646-9","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review boards approved this study (CHU de Qu\u00e9bec, #A13-2-1096; CHUM, #14.228; Cambridge Central Regional Ethics Committee, REC #03\/303 & #08\/H0306\/26; and Cambridge University Hospitals Foundation Trust Research and Development department, R&D #A085170 & #A091246) in accordance with the Declaration of Helsinki, and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to Publish declaration: not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}